| Identification |
| Name: | H-1152Glycyl, Dihydrochloride |
| Synonyms: | (2S)-4-(Aminoacetyl)hexahydro -2-methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]-1H-1,4-diazepine Dihydrochloride;2-Amino-1-[(3S)-hexahydro-3-methyl-4-[(4-methyl-5-isoquinolinyl)sulfonyl]-1H-1,4-diazepin-1-yl]ethanone Hydrochloride;H-1152Glycyl, Dihydrochloride;(S)-(+)-4-Glycyl-2-methyl-1-[(4-methyl-5-isoquinolinyl) sulfonyl]-hexahydro-1H-1,4-diazepine dihydrochloride |
| CAS: | 913844-45-8 |
| Molecular Formula: | C18H26Cl2N4O3S |
| Molecular Weight: | 0 |
| Molecular Structure: |
![(C18H26Cl2N4O3S) (2S)-4-(Aminoacetyl)hexahydro -2-methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]-1H-1,4-diazepine Dihy...](https://img.guidechem.com/structure/913844-45-8.gif) |
| Properties |
| Biological Activity: | Glycyl analog of the Rho-kinase inhibitor H 1152 dihydrochloride ((S)-(+)-2-Methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]-hexahydro-1H-1,4-diazepine dihydrochloride ) that displays improved ROCKII selectivity. IC 50 values are 0.0118, 2.35, 2.57, 3.26, > 10 and >10 μ M for ROCKII, Aurora A, CAMKII, PKG, PKA and PKC respectively. |
| Usage: | A glycyl analog of Rho-kinase (ROCK) inhibitor that inhibits ROCK with an improved selectitity; for treatment of hypertension and arteriosclerosis. |
| Safety Data |
| |
 |
